Confidentiality Concerns Raised by DNA-Based Tests in the Market-Driven Managed Care Setting
In a policy climate where incentives to cherry pick are minimized, Managed Care Organizations can implement practices that safeguard medical privacy to the extent that data is protected from falling into the hands of third parties who could misuse it to discriminate. To the extent that these practices have been codified into the regulatory Network of the Health Insurance Portability and Accountability Act (HIPAA) Consumers may be able to rest easy about their genetic data being revealed to third parties who may discriminate. However, there are limitations to the use of policy instruments to prevent the discrimination of an entire genre of clients by market driven managed care organizations. Policy measures, to assure that knowledge of genetic conditions and their future costs would not be used by market driven managed care organizations to implement institutional policies and products that would implicitly discriminate against a genre of clients with genetic conditions, present difficulties.
- Research Organization:
- The Research Foundation of State University of New York, Albany, NY
- Sponsoring Organization:
- USDOE - Office of Energy Research (ER)
- DOE Contract Number:
- FG02-97ER62430
- OSTI ID:
- 899030
- Country of Publication:
- United States
- Language:
- English
Similar Records
Genetic secrets: Protecting privacy and confidentiality in the genetic era. Final report
A New Appraisal- Lessons from the History of Efforts to Value Green and High-Performance Home Attributes in the United States